Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Kevzara for Treatment of RA

Sanofi Genzyme news release; 2017 May 22

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the US Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to 1 or more disease modifying antirheumatic drugs (DMARDs). In the US, Kevzara will be marketed by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi, in Tarrytown, NY.

Indication: Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling.

Dosage/administration: Kevzara may be used as monotherapy or in combination with methotrexate(MTX) or other conventional DMARDs. The recommended dosage of KEVZARA is 200 mg once every 2 weeks, administered as a subcutaneous injection.

Adverse effects: Most common adverse reactions are neutropenia, increased ALT, injection site erythema, upper respiratory infections, and urinary tract infections.

Citation:

Sanofi and Regeneron announce FDA approval of Kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients. [news release]. Paris, France, and Tarrytown, NY: Sanofi Genzyme May 22, 2017. http://genzyme.newshq.businesswire.com/press-release/sanofi-and-regeneron-announce-fda-approval-kevzara-sarilumab-treatment-moderately-seve. Accessed May 30, 2017.